Align Technology, Inc.

▲ Bull Case

• ◆Elliott fully executes SG&A compression: Board refreshment + management alignment drives SG&A from ~33% to 27-28% of revenue by FY2027 (vs. ALGN's own FY2021 SG&A of ~26.5%); operating margin reaches 21-22%; FCF ~$950M by FY2027; at 22x FCF = $240/share (+53%).
• ◆China and EMEA volume re-accelerate: China clear aligner recovery (post-COVID normalization) drives +15%/yr unit growth vs. base +8%; ALGN China segment revenue $0.9B → $1.5B by FY2029; combined with margin recovery creates double-digit EPS CAGR above model.
• ◆iTero Lumina upgrade cycle + exocad SaaS transition: Systems & Services revenue re-accelerates to +8-10%/yr; SaaS subscription model provides recurring revenue visibility; potential iTero spin or partnership surfaces hidden value; intrinsic re-rating to $260-280/share by FY2028.

▼ Bear Case

• ◆Margin recovery stalls: Elliott's program meets management resistance; SG&A remains ~31-32% of revenue through FY2027; operating margin stuck at 14-15%; FCF ~$430M by FY2027 at 14x = $86/share (-45%).
• ◆China competition + DTC aligner successors: Local Chinese competitors (Angelalign/EasySmile) gain 5-7pp market share; better-capitalized direct-to-consumer aligner brands erode ALGN's mild/moderate case ASPs by 3-4%/yr; revenue misses estimates; SG&A leverage never materializes.
• ◆Orthodontic recession sensitivity: Any macro downturn (ALGN is highly elective, $4K-8K avg. case cost) drives 20-25% volume decline; fixed cost base creates operating deleverage; FCF collapses; stock re-rates to 12-14x trough earnings = $80-100/share.

“The central debate is whether ALGN's margin compression represents a fixable cost structure that Elliott will unlock, or a structural re-rating of the business as the clear aligner market matures and competition intensifies. Bull side: ALGN's FY2021 peak operating margin of 24.7% proves that 20%+ operating margins are achievable at current revenue scale; the compression is self-inflicted (over-hiring, excess SG&A) not structural; Elliott has a clear mechanism (board seats, management alignment, SG&A targets); Q1 2026 volume acceleration proves market health; ALGN's moat (provider network, data flywheel, SmartTrack material) remains intact. Bear side: The SG&A bloat was built over 4 years with 4 consecutive misses on margin guidance; management credibility is low; Elliott has not yet achieved anything; local competitors in China are genuinely gaining; the high-margin clear aligner business is becoming more competitive at the lower case complexity end. Consensus: 18 Buy / 8 Hold / 2 Sell; median PT ~$215 (+37%). Street is constructive on the Elliott catalyst; the debate is speed and magnitude of margin recovery.”

• ◆Q2 2026 SG&A % of revenue showing improvement (SG&A < 31% of revenue)
• ◆Elliott board seats / management changes materializing in Q2-Q3 2026
• ◆Q2 2026 revenue growth sustained at +7%+ YoY
• ◆FY2026 operating margin exit rate exceeding 16% (H2 2026 improvement)
• ◆China volume data showing +10%+ YoY for 2 consecutive quarters
• ◆iTero strategic review outcome — sale/partnership at 3-4x revenue ($600M-800M)
• ◆FY2027 buyback authorization of $500M+ demonstrating capital return acceleration

• ◆Margin recovery fails / Elliott management impasse (25-30% probability) — core thesis is margin recovery; impasse = thesis fails
• ◆China volume stagnation or competitive market share loss to Angelalign/EasySmile (25-30% probability)
• ◆Macro recession / orthodontic volume collapse driving 20-25% revenue decline with operating deleverage (15-20% probability)
• ◆DTC aligner competitors at lower ASP eroding mild/moderate case revenue at -3%/yr (15-20% probability)
• ◆iTero competitive pressure from Medit/3Shape causing Systems & Services revenue decline of -2-3%/yr (15-20% probability)